Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Summary

To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Timeline

Start

2020-01-20

Primary completion

2023-06-01

Completion

2023-06-01

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications